Advanced search
1 file | 4.48 MB Add to list

Structure-activity relationships of valine, tert-leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA

(2022) RSC MEDICINAL CHEMISTRY. 13(2). p.156-174
Author
Organization
Project
Abstract
Synthetic cannabinoid receptor agonists (SCRAs) remain one the most prevalent classes of new psychoactive substances (NPS) worldwide, and examples are generally poorly characterised at the time of first detection. We have synthesised a systematic library of amino acid-derived indole-, indazole-, and 7-azaindole-3-carboxamides related to recently detected drugs ADB-BUTINACA, APP-BUTINACA and ADB-P7AICA, and characterised these ligands for in vitro binding and agonist activity at cannabinoid receptor subtypes 1 and 2 (CB1 and CB2), and in vivo cannabimimetic activity. All compounds showed high affinity for CB1 (K-i 0.299-538 nM) and most at CB2 (K-i = 0.912-2190 nM), and most functioned as high efficacy agonists of CB1 and CB2 in a fluorescence-based membrane potential assay and a beta arr2 recruitment assay (NanoBiT (R)), with some compounds being partial agonists in the NanoBiT (R) assay. Key structure-activity relationships (SARs) were identified for CB1/CB2 binding and CB1/CB2 functional activities; (1) for a given core, affinities and potencies for tert-leucinamides (ADB-) > valinamides (AB-) >> phenylalaninamides (APP-); (2) for a given amino acid side-chain, affinities and potencies for indazoles > indoles >> 7-azaindoles. Radiobiotelemetric evaluation of ADB-BUTINACA, APP-BUTINACA and ADB-P7AICA in mice demonstrated that ADB-BUTINACA and ADB-P7AICA were cannabimimetic at 0.1 mg kg(-1) and 10 mg kg(-1) doses, respectively, as measured by pronounced decreases in core body temperature. APP-BUTINACA failed to elicit any hypothermic response up to the maximally tested 10 mg kg(-1) dose, yielding an in vivo potency ranking of ADB-BUTINACA > ADB-P7AICA > APP-BUTINACA.
Keywords
PSYCHOACTIVE SUBSTANCES, CUMYL-PICA, PHARMACOLOGY, CB1, CONSUMPTION, GENERATION, FUBINACA, SEIZURES, INDOLE

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • application/octet-stream
    • |
    • 4.48 MB

Citation

Please use this url to cite or link to this publication:

MLA
Sparkes, Eric, et al. “Structure-Activity Relationships of Valine, Tert-Leucine, and Phenylalanine Amino Acid-Derived Synthetic Cannabinoid Receptor Agonists Related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA.” RSC MEDICINAL CHEMISTRY, vol. 13, no. 2, 2022, pp. 156–74, doi:10.1039/d1md00242b.
APA
Sparkes, E., Cairns, E. A., Kevin, R. C., Lai, F., Grafinger, K. E., Chen, S., … Banister, S. D. (2022). Structure-activity relationships of valine, tert-leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA. RSC MEDICINAL CHEMISTRY, 13(2), 156–174. https://doi.org/10.1039/d1md00242b
Chicago author-date
Sparkes, Eric, Elizabeth A. Cairns, Richard C. Kevin, Felcia Lai, Katharina Elisabeth Grafinger, Shuli Chen, Marie Deventer, et al. 2022. “Structure-Activity Relationships of Valine, Tert-Leucine, and Phenylalanine Amino Acid-Derived Synthetic Cannabinoid Receptor Agonists Related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA.” RSC MEDICINAL CHEMISTRY 13 (2): 156–74. https://doi.org/10.1039/d1md00242b.
Chicago author-date (all authors)
Sparkes, Eric, Elizabeth A. Cairns, Richard C. Kevin, Felcia Lai, Katharina Elisabeth Grafinger, Shuli Chen, Marie Deventer, Ross Ellison, Rochelle Boyd, Lewis J. Martin, Iain S. McGregor, Roy R. Gerona, David E. Hibbs, Volker Auwaerter, Michelle Glass, Christophe Stove, and Samuel D. Banister. 2022. “Structure-Activity Relationships of Valine, Tert-Leucine, and Phenylalanine Amino Acid-Derived Synthetic Cannabinoid Receptor Agonists Related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA.” RSC MEDICINAL CHEMISTRY 13 (2): 156–174. doi:10.1039/d1md00242b.
Vancouver
1.
Sparkes E, Cairns EA, Kevin RC, Lai F, Grafinger KE, Chen S, et al. Structure-activity relationships of valine, tert-leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA. RSC MEDICINAL CHEMISTRY. 2022;13(2):156–74.
IEEE
[1]
E. Sparkes et al., “Structure-activity relationships of valine, tert-leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA,” RSC MEDICINAL CHEMISTRY, vol. 13, no. 2, pp. 156–174, 2022.
@article{8754583,
  abstract     = {{Synthetic cannabinoid receptor agonists (SCRAs) remain one the most prevalent classes of new psychoactive substances (NPS) worldwide, and examples are generally poorly characterised at the time of first detection. We have synthesised a systematic library of amino acid-derived indole-, indazole-, and 7-azaindole-3-carboxamides related to recently detected drugs ADB-BUTINACA, APP-BUTINACA and ADB-P7AICA, and characterised these ligands for in vitro binding and agonist activity at cannabinoid receptor subtypes 1 and 2 (CB1 and CB2), and in vivo cannabimimetic activity. All compounds showed high affinity for CB1 (K-i 0.299-538 nM) and most at CB2 (K-i = 0.912-2190 nM), and most functioned as high efficacy agonists of CB1 and CB2 in a fluorescence-based membrane potential assay and a beta arr2 recruitment assay (NanoBiT (R)), with some compounds being partial agonists in the NanoBiT (R) assay. Key structure-activity relationships (SARs) were identified for CB1/CB2 binding and CB1/CB2 functional activities; (1) for a given core, affinities and potencies for tert-leucinamides (ADB-) > valinamides (AB-) >> phenylalaninamides (APP-); (2) for a given amino acid side-chain, affinities and potencies for indazoles > indoles >> 7-azaindoles. Radiobiotelemetric evaluation of ADB-BUTINACA, APP-BUTINACA and ADB-P7AICA in mice demonstrated that ADB-BUTINACA and ADB-P7AICA were cannabimimetic at 0.1 mg kg(-1) and 10 mg kg(-1) doses, respectively, as measured by pronounced decreases in core body temperature. APP-BUTINACA failed to elicit any hypothermic response up to the maximally tested 10 mg kg(-1) dose, yielding an in vivo potency ranking of ADB-BUTINACA > ADB-P7AICA > APP-BUTINACA.}},
  author       = {{Sparkes, Eric and Cairns, Elizabeth A. and Kevin, Richard C. and Lai, Felcia and Grafinger, Katharina Elisabeth and Chen, Shuli and Deventer, Marie and Ellison, Ross and Boyd, Rochelle and Martin, Lewis J. and McGregor, Iain S. and Gerona, Roy R. and Hibbs, David E. and Auwaerter, Volker and Glass, Michelle and Stove, Christophe and Banister, Samuel D.}},
  issn         = {{2632-8682}},
  journal      = {{RSC MEDICINAL CHEMISTRY}},
  keywords     = {{PSYCHOACTIVE SUBSTANCES,CUMYL-PICA,PHARMACOLOGY,CB1,CONSUMPTION,GENERATION,FUBINACA,SEIZURES,INDOLE}},
  language     = {{eng}},
  number       = {{2}},
  pages        = {{156--174}},
  title        = {{Structure-activity relationships of valine, tert-leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA}},
  url          = {{http://doi.org/10.1039/d1md00242b}},
  volume       = {{13}},
  year         = {{2022}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: